454 related articles for article (PubMed ID: 32155826)
1. Immune Response Dysfunction in Chronic Lymphocytic Leukemia: Dissecting Molecular Mechanisms and Microenvironmental Conditions.
Arruga F; Gyau BB; Iannello A; Vitale N; Vaisitti T; Deaglio S
Int J Mol Sci; 2020 Mar; 21(5):. PubMed ID: 32155826
[TBL] [Abstract][Full Text] [Related]
2. Molecular Interactions Between Innate and Adaptive Immune Cells in Chronic Lymphocytic Leukemia and Their Therapeutic Implications.
Haseeb M; Anwar MA; Choi S
Front Immunol; 2018; 9():2720. PubMed ID: 30542344
[TBL] [Abstract][Full Text] [Related]
3. T Cells in Chronic Lymphocytic Leukemia: A Two-Edged Sword.
Vlachonikola E; Stamatopoulos K; Chatzidimitriou A
Front Immunol; 2020; 11():612244. PubMed ID: 33552073
[TBL] [Abstract][Full Text] [Related]
4. Survival and Immunosuppression Induced by Hepatocyte Growth Factor in Chronic Lymphocytic Leukemia.
Giannoni P; Cutrona G; Totero D
Curr Mol Med; 2017; 17(1):24-33. PubMed ID: 28231754
[TBL] [Abstract][Full Text] [Related]
5. Immune Dysfunctions and Immune-Based Therapeutic Interventions in Chronic Lymphocytic Leukemia.
Griggio V; Perutelli F; Salvetti C; Boccellato E; Boccadoro M; Vitale C; Coscia M
Front Immunol; 2020; 11():594556. PubMed ID: 33312177
[TBL] [Abstract][Full Text] [Related]
6. Chronic lymphocytic leukemia cells are active participants in microenvironmental cross-talk.
van Attekum MH; Eldering E; Kater AP
Haematologica; 2017 Sep; 102(9):1469-1476. PubMed ID: 28775118
[TBL] [Abstract][Full Text] [Related]
7. T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers.
Palma M; Gentilcore G; Heimersson K; Mozaffari F; Näsman-Glaser B; Young E; Rosenquist R; Hansson L; Österborg A; Mellstedt H
Haematologica; 2017 Mar; 102(3):562-572. PubMed ID: 27927767
[TBL] [Abstract][Full Text] [Related]
8. Targeting the Adenosinergic Axis in Chronic Lymphocytic Leukemia: A Way to Disrupt the Tumor Niche?
Vaisitti T; Arruga F; Deaglio S
Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29649100
[TBL] [Abstract][Full Text] [Related]
9. Beyond bystanders: Myeloid cells in chronic lymphocytic leukemia.
Hanna BS; Öztürk S; Seiffert M
Mol Immunol; 2019 Jun; 110():77-87. PubMed ID: 29173971
[TBL] [Abstract][Full Text] [Related]
10. The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
Zou YX; Zhu HY; Li XT; Xia Y; Miao KR; Zhao SS; Wu YJ; Wang L; Xu W; Li JY
Hematol Oncol; 2019 Oct; 37(4):392-400. PubMed ID: 31420873
[TBL] [Abstract][Full Text] [Related]
11. The chronic lymphocytic leukemia microenvironment: Beyond the B-cell receptor.
Choi MY; Kashyap MK; Kumar D
Best Pract Res Clin Haematol; 2016 Mar; 29(1):40-53. PubMed ID: 27742071
[TBL] [Abstract][Full Text] [Related]
12. Cross-talk between leukemic and immune cells at the tumor microenvironment in chronic lymphocytic leukemia: An update review.
Taghiloo S; Asgarian-Omran H
Eur J Haematol; 2024 Jul; 113(1):4-15. PubMed ID: 38698678
[TBL] [Abstract][Full Text] [Related]
13. CD40 signaling instructs chronic lymphocytic leukemia cells to attract monocytes via the CCR2 axis.
van Attekum MHA; van Bruggen JAC; Slinger E; Lebre MC; Reinen E; Kersting S; Eldering E; Kater AP
Haematologica; 2017 Dec; 102(12):2069-2076. PubMed ID: 28971904
[TBL] [Abstract][Full Text] [Related]
14. Leukemic cell-secreted interleukin-9 suppresses cytotoxic T cell-mediated killing in chronic lymphocytic leukemia.
Boncompagni G; Tatangelo V; Lopresti L; Ulivieri C; Capitani N; Tangredi C; Finetti F; Marotta G; Frezzato F; Visentin A; Ciofini S; Gozzetti A; Bocchia M; Calzada-Fraile D; Martin Cofreces NB; Trentin L; Patrussi L; Baldari CT
Cell Death Dis; 2024 Feb; 15(2):144. PubMed ID: 38360867
[TBL] [Abstract][Full Text] [Related]
15. Idelalisib and caffeine reduce suppression of T cell responses mediated by activated chronic lymphocytic leukemia cells.
Hock BD; MacPherson SA; McKenzie JL
PLoS One; 2017; 12(3):e0172858. PubMed ID: 28257435
[TBL] [Abstract][Full Text] [Related]
16. CD84 regulates PD-1/PD-L1 expression and function in chronic lymphocytic leukemia.
Lewinsky H; Barak AF; Huber V; Kramer MP; Radomir L; Sever L; Orr I; Mirkin V; Dezorella N; Shapiro M; Cohen Y; Shvidel L; Seiffert M; Herishanu Y; Becker-Herman S; Shachar I
J Clin Invest; 2018 Dec; 128(12):5465-5478. PubMed ID: 30277471
[TBL] [Abstract][Full Text] [Related]
17. Immunosuppressive Treg cells acquire the phenotype of effector-T cells in chronic lymphocytic leukemia patients.
De Matteis S; Molinari C; Abbati G; Rossi T; Napolitano R; Ghetti M; Di Rorà AGL; Musuraca G; Lucchesi A; Rigolin GM; Cuneo A; Calistri D; Fattori PP; Bonafè M; Martinelli G
J Transl Med; 2018 Jun; 16(1):172. PubMed ID: 29925389
[TBL] [Abstract][Full Text] [Related]
18. T-cells in chronic lymphocytic leukemia: Guardians or drivers of disease?
Roessner PM; Seiffert M
Leukemia; 2020 Aug; 34(8):2012-2024. PubMed ID: 32457353
[TBL] [Abstract][Full Text] [Related]
19. Nurse-Like Cells and Chronic Lymphocytic Leukemia B Cells: A Mutualistic Crosstalk inside Tissue Microenvironments.
Fiorcari S; Maffei R; Atene CG; Potenza L; Luppi M; Marasca R
Cells; 2021 Jan; 10(2):. PubMed ID: 33499012
[TBL] [Abstract][Full Text] [Related]
20. Chronic lymphocytic leukemia cells are activated and proliferate in response to specific T helper cells.
Os A; Bürgler S; Ribes AP; Funderud A; Wang D; Thompson KM; Tjønnfjord GE; Bogen B; Munthe LA
Cell Rep; 2013 Aug; 4(3):566-77. PubMed ID: 23933259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
